Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2016 05:30 ET | Source: Opthea

Opthea's Phase 1 Data From Wet AMD Clinical Trial Presented at EURETINA Congress 2016

MELBOURNE, AUSTRALIA--(Marketwired - Sep 12, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY), a developer of novel biologic therapies for the treatment of eye diseases, today announced that data...
July 25, 2016 19:15 ET | Source: Opthea

Opthea Reports Positive Data From Wet AMD Clinical Trial

MELBOURNE, AUSTRALIA--(Marketwired - Jul 25, 2016) - Opthea Limited (ASX: OPT) Phase 1 dose escalation study met primary objective demonstrating OPT-302 safety and...
July 25, 2016 02:15 ET | Source: Opthea

Opthea to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-302

MELBOURNE, AUSTRALIA--(Marketwired - Jul 25, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY), a developer of novel biologic therapies for the treatment of eye diseases, will host a conference call...
May 05, 2016 05:30 ET | Source: Opthea

Opthea Doses First Patient in Phase 2A Dose Expansion Study for OPT-302 in Wet AMD

MELBOURNE, AUSTRALIA--(Marketwired - May 5, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY) Phase 2A dose expansion follows successful completion of the 28 day safety...
April 21, 2016 05:30 ET | Source: Opthea

Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective

MELBOURNE, AUSTRALIA--(Marketwired - Apr 21, 2016) - Opthea Limited (ASX: OPT) (OTCQX: CKDXY) OPT-302 safe and well tolerated as monotherapy and in combination with...